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Viruses have evolved strategies to protect infected cells from apoptotic clearance. We present evidence that HIV-1
possesses a mechanism to protect infected macrophages from the apoptotic effects of the death ligand TRAIL (tumor
necrosis factor–related apoptosis-inducing ligand). In HIV-1–infected macrophages, the viral envelope protein induced
macrophage colony-stimulating factor (M-CSF). This pro-survival cytokine downregulated the TRAIL receptor TRAIL-R1/
DR4 and upregulated the anti-apoptotic genes Bfl-1 and Mcl-1. Inhibition of M-CSF activity or silencing of Bfl-1 and
Mcl-1 rendered infected macrophages highly susceptible to TRAIL. The anti-cancer agent Imatinib inhibited M-CSF
receptor activation and restored the apoptotic sensitivity of HIV-1–infected macrophages, suggesting a novel strategy
to curtail viral persistence in the macrophage reservoir.
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Introduction
The envelope glycoproteins of primate lentiviruses harbor
domains that mediate the interaction with receptor/co-
receptor proteins on the surface of susceptible cells and
promote fusion between viral and cellular membranes during
virus entry [1]. However, some studies suggest that activities of
humanlentiviralenvelopeproteinsextendbeyondtheirrolein
viral entry. For example, the envelope protein signals through
receptorandco-receptormoleculesafterenvelopebinding,an
activity that may alter target cell function to increase the cell’s
permissivity to virus infection [2,3]. In addition, the HIV-1
envelope, like other retroviral envelope proteins [4], contains
domains that interact with the intracellular signal trans-
duction machinery to promote changes in cell function [5,6],
such as the induction of pro-inﬂammatory cytokines [7].
The prevention of apoptosis of the infected cell is an
important modiﬁcation to host cell function, particularly
during chronic viral infections [8]. As a consequence, viruses
have evolved measures that either confer resistance to
apoptotic cell death or kill the cells delivering the apoptotic
signal. Adenoviruses encode RID proteins that promote the
internalization of death receptors for Fas, tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL), and tumor
necrosis factor receptor 1 (TNFR1), thereby allowing infected
cells to withstand these apoptotic stimuli [9–11]. As part of a
counterattack strategy, human cytomegalovirus upregulates
death-inducing ligands on the infected cell, triggering
apoptosis of human cytomegalovirus–speciﬁc T cells [12].
Most of the data on HIV-1 immune evasion strategies have
been derived from experiments in lymphocytes. For example,
the HIV-1 Nef gene has been shown to block the function of
ASK 1 (apoptosis signal-regulating kinase 1) in infected
lymphocytes to protect these cells from Fas and TNFR-
mediated apoptosis [13]. At the same time, HIV-1 Nef induces
Fas ligand expression on infected cells to kill cytotoxic T cells
expressing Fas on the cell surface [14]. Despite the existence
of viral mechanisms to protect lymphocytes from the host
apoptotic response, productively infected lymphocytes are
rapidly cleared by the cytopathic effects of virus infection
[15]. By comparison, the turnover of infected macrophages is
slow. Extrapolation of the decay characteristics of plasma
virions during highly active antiretroviral therapy suggests
that the half-life of the infected macrophage reservoir in the
tissues is on the order of 2–4 wk [15]. However, a greater half-
life is suggested by studies with highly pathogenic SHIV
(simian immunodeﬁciency virus [SIV]/HIV chimera) variants,
which demonstrated no decay in the macrophage reservoir
over a 3–4-mo interval when viral spread was prevented by
the antiretroviral PMPA [16]. Whether HIV-1 has a mecha-
nism to sustain the persistence of infected macrophages is
unknown.
Results
The HIV-1 Envelope Regulates the Pro-Survival Cytokine
M-CSF
HIV-1–infected macrophages release the pro-survival
cytokine M-CSF (macrophage colony-stimulating factor) and
the b-chemokines MIP-1a and MIP-1b [17,18]. To character-
ize the biological role of M-CSF in HIV-1 replication, we
initially identiﬁed the viral gene product responsible for its
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macrophages were infected with vesicular stomatitis virus
(VSV)–pseudotyped, X4-tropic viruses containing inactivat-
ing mutations in structural and accessory genes. Levels of
virus production (extracellular reverse transcriptase [RT]
activity) and M-CSF release were monitored at different
intervals after infection. While the accessory proteins Vpu,
Vif, Nef, and Vpr were relatively dispensable for the
induction of M-CSF (unpublished data), the release of M-
CSF by macrophages infected with an HIV-1 envelope-minus
variant (HIV-1LAIDenv) was impaired relative to macrophages
infected with a wild-type virus, despite indistinguishable
levels of virus production in wild-type– and Denv-infected
cultures (Figure 1A). There was a statistically signiﬁcant (p ¼
0.001) relationship between envelope and M-CSF when peak
M-CSF levels in HIV-1WT, HIV-1D env, and mock-infected
macrophages from nine independent experiments were
compared (Figure 1B). In addition, during infection of
macrophages with wild-type R5-tropic HIV-1, M-CSF pro-
duction was signiﬁcantly induced over mock-infected cul-
tures (p ¼ 0.003, n ¼ 15; Figure 1C).
The HIV-1 envelope protein induces signals through the
chemokine receptors that inﬂuence the expression of cellular
genes [19,20]. Macrophage infection by HIV-1 is mediated
primarily by the co-receptor CCR5 [1]. Since M-CSF was
induced by X4-tropic viruses that are unable to use CCR5 on
macrophages (Figure 1A and 1B), the induction appeared to
be independent of co-receptor use. Macrophages infected
with a pseudotyped HIV-1 variant that harbored a mutation
in the CD4 binding epitope of envelope [21] also induced M-
CSF production. However, M-CSF was not induced when
macrophages were pulsed with gradient-puriﬁed R5-tropic
HIV-1ADA virions or with HIV-1ADA Denv virions (Figure S1).
Collectively, these results indicate that the induction of M-
CSF by the viral envelope glycoprotein was independent of
receptor or co-receptor interactions. In addition, de novo
synthesized envelope, but not virion-associated envelope,
induced M-CSF production.
HIV-1 Envelope Restricts Expression of Death Receptors
on Infected Macrophages
Since cytokines can counteract apoptotic signals [22,23], we
analyzed whether the differential expression of M-CSF in
HIV-1 wild-type– and Denv-infected macrophages affected
the expression of apoptotic mediators in these cells. When
analyzed using pathway-speciﬁc gene arrays, macrophages
infected with a Denv virus but not with a wild-type virus
expressed greatly elevated mRNA levels for the TRAIL Death
Receptor TRAIL-R1/DR4 (Figure S2). This reﬂected an
increase in surface TRAIL-R1 on HIV-1 Denv-infected
macrophages compared with wild-type–infected macro-
phages (23% TRAIL-R1 positive for Denv versus 6% for
wild-type–infected macrophages; Figure 2A). Furthermore, in
a comparison of seven independent experiments, a statisti-
cally signiﬁcant difference in TRAIL-R1 expression was
observed following infection of macrophages with envelope
minus virus relative to wild-type– and mock-infected macro-
phages (p , 0.001; Figure 2B). However, expression of death
receptors for Fas ligand and TWEAK (tumor necrosis factor–
like weak inducer of apoptosis) were not affected by HIV-1
infection (Figure 2A).
We next examined whether the differential expression of
TRAIL-R1 on HIV-1 wild-type– and Denv-infected macro-
phages conferred differential sensitivity to TRAIL. Macro-
phages infected with a Denv virus were highly susceptible to
TRAIL killing, as evidenced by activation of caspase 3, a
hallmark of TRAIL-dependent apoptosis (Figure 2C). In
contrast, caspase 3 levels in wild-type–infected macrophages
in both the presence and absence of TRAIL were similar to
levels in uninfected macrophages (Figure 2C). TRAIL also
selectively curtailed the survival of macrophages infected
with a Denv virus. In the presence of TRAIL, the half-life of
m a c r o p h a g e si n f e c t e dw i t haDenv virus was ;1.7 d,
compared with ;4.6 d for wild-type virus and ;3.5 d for
mock-infected cells (Figure 2D). In the absence of TRAIL,
Denv-infected macrophages also possessed the shortest half-
life, ;38 d, while wild-type– or mock-infected macrophages
exhibited a half-life of ;70 d and ;100 d, respectively (Figure
2E). We also determined the relative concentrations of TRAIL
required to impact viability and virus output of macrophage
cultures infected with wild-type and Denv viruses. In macro-
phages infected with a Denv HIV-1 variant, a TRAIL
concentration of 3 ng/ml
 1 produced a 50% reduction in
cell viability and virus output (Figure 2F and 2G). In contrast,
more than 30 ng/ml
 1 and 50 ng/ml
 1 of TRAIL was required
for a 50% reduction in viability and virus output, respec-
tively, from wild-type–infected macrophages (Figure 2F and
2G). HIV-1 envelope also rendered infected macrophages
resistant to TRAIL on the surface of activated T lymphocytes.
When activated CD8
þ T cells (;16% TRAIL positive;
unpublished data) were co-cultured with infected macro-
phages, virus output from HIV-1 Denv-infected macrophages
was reduced by ;90%, but virus output from wild-type–
infected macrophages was not affected (Figure 2H). Collec-
tively, these results indicate that HIV-1–infected macro-
phages are resistant to TRAIL and that the viral envelope
glycoprotein is required for this resistance.
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Author Summary
Much of our understanding regarding mechanisms of HIV-1
persistence has been derived from studies with lymphocytes.
However, mechanisms governing persistent infection of macro-
phages are less well understood. We investigated whether HIV-1
modulates macrophage function in a way that promotes their persist
infection. We focused on a cytokine called macrophage colony-
stimulating factor (M-CSF), because this pro-survival factor is induced
upon infection by HIV-1. We found that the viral envelope gene was
necessary for M-CSF induction of macrophages. M-CSF upregulated
anti-apoptotic genes in macrophages and restricted the expression
of the death receptor (tumor necrosis factor–related apoptosis-
inducing ligand [TRAIL]-R1). As a consequence, HIV-1–infected
macrophages were resistant to the apoptotic effects of TRAIL. If M-
CSF was blocked by antibody or if the anti-apoptotic genes were
silenced by RNA interference, the apoptotic sensitivity of HIV-1–
infected macrophages was restored. Also, the anti-cancer drug
Imatinib, which impairs activation of the M-CSF receptor, promoted
the death of HIV-1–infected macrophages but not of uninfected
macrophages. We believe that HIV-1 regulates M-CSF to extend
macrophage survival and promote viral persistence in the host.
Agents that interfere with M-CSF signaling, such as Imatinib, warrant
further examination for activity against macrophage reservoirs in
vivo.HIV-1 Envelope Regulates TRAIL Sensitivity via M-CSF
The viral envelope glycoprotein induced the production of
M-CSF in infected macrophages (Figure 1). Since cytokines
can promote cell survival by opposing apoptotic signals
[22,23], we examined whether M-CSF was required for the
resistance of wild type–infected macrophages to TRAIL.
When M-CSF was neutralized in macrophage cultures
infected with wild-type HIV-1, surface TRAIL-R1 expression
increased (Figure 3A). In parallel, neutralization of M-CSF in
macrophage cultures infected with wild-type R5-tropic HIV-1
elevated TRAIL-R1 expression (Figure S4A–S4C). Conversely,
addition of M-CSF to the culture downregulated TRAIL-R1
expression on macrophages infected with an envelope
defective virus (Figure 3A). M-CSF neutralization restored
TRAIL sensitivity to macrophages infected with wild-type
virus; macrophage viability was reduced by 75% and virus
output by 85% when M-CSF was neutralized in these cultures
(Figure 3B and 3C). M-CSF neutralization rendered wild-type
virus–infected macrophages as sensitive to TRAIL as macro-
phages infected with Denv virus. Together, these results
demonstrate that M-CSF is required for the ability of the viral
envelope glycoprotein to confer TRAIL resistance to infected
macrophages.
The Anti-Apoptotic Genes Bfl-1 and Mcl-1 Mediate TRAIL
Resistance
We next set out to identify host factors through which the
viral envelope regulated the susceptibility of infected macro-
phages to TRAIL. We targeted the mRNA analysis to cellular
genes involved in the TRAIL apoptosis pathway. We
predicted that genes that mediate the protective effect of
the viral envelope would also be upregulated by M-CSF. Two
genes, Bﬂ-1 and Mcl-1, which inhibit mitochondrial-depend-
ent apoptosis [24, 25], were upregulated in macrophages
infected with wild-type HIV-1 and in mock-infected macro-
phages that had been stimulated with M-CSF (Figure 4A).
However, Bﬂ-1 and Mcl-1 were not upregulated in macro-
phages infected with a Denv virus (Figure 4A). To determine
whether these anti-apoptotic genes were necessary for HIV-1
to render macrophages resistant to TRAIL, the resistance of
infected macrophages to TRAIL was examined after silencing
these genes by RNA interference. In macrophages, RNA
interference achieved a 70%–75% knockdown of Bﬂ-1 and
Mcl-1 proteins and mRNA when assessed by Western blotting
and quantitative RT-PCR, (reverse transcription PCR),
respectively (Figure 4B and 4C). Silencing of either Bﬂ-1 or
Mcl-1 restored the susceptibility of wild-type–infected macro-
phages to TRAIL (Figure 4D). Levels of caspase activation in
wild-type–infected macrophages in which Bﬂ-1 or Mcl-1 had
been silenced approached levels observed in wild-type–
infected macrophages in which M-CSF had been neutralized
(Figure 4D). In the absence of TRAIL, neither Bﬂ-1/Mcl-1
silencing nor M-CSF neutralization had a signiﬁcant impact
on the levels of macrophage apoptosis (Figure 4D). Three
other host genes, cIAP-1, cIAP-2, and XIAP, which antagonize
caspase activation [24, 26], were upregulated by the viral
Figure 1. HIV-1 Envelope-Dependent M-CSF Induction by Infected Macrophages
(A) Levels of virus (upper panels) and M-CSF (lower panels) production by macrophages following infection with VSV-envelope pseudotyped X4 HIV-1
variants (HIV-1LAI) containing intact (WT) or defective (Denv) HIV-1 envelope genes. Results obtained with macrophages from three independent donors
are shown.
(B) Statistical analysis of peak mean M-CSF release by pseudotyped X4-tropic HIV-1LAIWT, HIV-1LAIDenv or mock-infected macrophages (ANOVA; error
bars, SEM), and (C) by macrophages infected with R5-tropic HIV-1ADAWT or mock-infected (t-test; error bars, SEM).
doi:10.1371/journal.ppat.0030134.g001
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to the induction of M-CSF release. From similar RNA
interference experiments, these IAP genes conferred moder-
ate resistance of wild-type–infected macrophages to TRAIL-
mediated apoptosis (Figure S3 and unpublished data).
Collectively, these results demonstrate that HIV-1 envelope
glycoprotein in macrophages induces M-CSF, which in turn
opposes the apoptotic effects of TRAIL by inducing the anti-
apoptotic proteins Bﬂ-1 and Mcl-1.
Imatinib Blocks M-CSF Function and Restores TRAIL
Sensitivity to Infected Macrophages
The aforementioned results predict that agents that
interfere with the function of M-CSF or of its receptor would
antagonize HIV-19s ability to protect infected macrophages
from TRAIL-mediated killing. The anti-cancer drug Imatinib
inhibits the tyrosine kinase activity of the bcr-abl oncogene
and also shows considerable selectivity and efﬁcacy toward
the intrinsic tyrosine kinase activity of the M-CSF receptor
Figure 2. Death Receptor Expression on Macrophages Infected with Wild-Type or Envelope-Minus HIV-1 Variants
(A) Macrophages were infected with VSV-pseudotyped wild-type HIV-1 (HIV-1HSAWT) or envelope-minus (HIV-1HSADenv) variants expressing HSA in
place of Vpr. Levels of TRAIL-R1, Fas, and TWEAK-R expression on infected (HSA positive) cells was determined by flow cytometry.
(B) Statistical analysis of mean TRAIL-R1 expression from macrophages from seven donors infected with pseudotyped HIV-1HSA wild-type or envelope-
minus viruses relative to mock-infected (ANOVA; error bars, SEM).
(C) The HIV-1 envelope negates macrophage susceptibility to apoptosis by TRAIL. Macrophages were infected with pseudotyped wild-type or Denv
minus HIV-1LAI variants. At 8 d post-infection, cultures were incubated with soluble TRAIL (100 ng/ml
 1). Apoptosis was determined by ELISA for active
(cleaved) caspase 3. The viral envelope increases macrophage survival in the presence of TRAIL. Eight days after infection with pseudotyped HIV-1LAI
wild-type or Denv viruses, macrophages were maintained with (D) or without (E) soluble TRAIL (100 ng/ml
 1), and the percentage of viable cells (cell
death ELISA) remaining over time was determined. Macrophage half-life was calculated from the linear regression slope over 24 h, compared by
ANOVA, and expressed as mean value in days 6 SEM. Concentrations of TRAIL required to impact viability and virus output in macrophages infected
with wild-type and Denv HIV-1 variants. Macrophages infected with HIV-1LAI wild-type or Denv viruses were incubated with increasing concentrations of
soluble TRAIL and cell viability (F) and virus production (G) were determined after 16 h.
(H) Activated CD8
þT cells selectively suppress virus production by HIV-1 Denv-infected macrophages. Wild-type and Denv HIV-1–infected macrophages
were incubated with anti-CD3/CD28 stimulated autologous CD8
þTRAIL
þT lymphocytes for 4 h. Virus production was determined after an additional 24
h. T cells were pre-incubated with recombinant TRAIL-R1 or control receptor (5 lg/ml
 1) for 1 h prior to co-culture.
doi:10.1371/journal.ppat.0030134.g002
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HIV-1 Envelope and Macrophage Apoptosis[27]. Therefore, we examined Imatinib for its potential to kill
HIV-1–infected macrophages. The M-CSF receptor under-
goes autophosphorylation after ligand binding [27]. At
concentrations obtainable in vivo, Imatinib inhibited recep-
tor phosphorylation in primary human macrophages (Figure
5A), indicating that Imatinib blocked signaling by the M-CSF
receptor in human macrophages. Furthermore, while TRAIL-
R1 expression in wild-type virus–infected macrophages was
similar to uninfected macrophages, addition of Imatinib
increased TRAIL-R1 expression to levels similar to that of
Denv-infected macrophages (Figure 5B and 5C). The eleva-
tion of TRAIL-R1 expression on wild-type–infected macro-
phages by Imatinib was consistently observed on cells from
three donors (p , 0.001), and Imatinib did not alter TRAIL-
R1 levels on macrophages infected with an envelope-minus
variant (Figure 5C). Furthermore, Imatinib had no effect on
TRAIL-R1 expression in uninfected macrophages (Figure 5B
and 5C). Imatinib restored the sensitivity of wild-type HIV-1–
infected macrophages to TRAIL and augmented TRAIL
susceptibility beyond that of Denv-infected macrophages.
Using Annexin V and propidium iodide to stain for apoptotic
cells, the addition of Imatinib followed by TRAIL caused
HIV-1–infected macrophages to undergo apoptosis (Figure
5D). In the absence of stimuli, infected macrophages under-
went a low level of apoptosis, which was not enhanced by
TRAIL. Importantly, Imatinib, TRAIL, or their combination
did not promote TRAIL-R1 expression or apoptosis in
uninfected macrophages present in the cultures (Figure 5D).
Analysis of apoptosis in HIV-1–infected macrophages by
DNA fragmentation further conﬁrmed that Imatinib negated
the resistance of wild-type–infected macrophages to TRAIL
and facilitated extensive apoptosis, equivalent to macro-
phages infected with a Denv virus and exposed to TRAIL
(Figure 5E). Macrophages infected with an R5-tropic wild-
type HIV-1 were similarly resistant to TRAIL-mediated
apoptosis. Imatinib likewise rendered these cells highly
sensitive to apoptosis by TRAIL (Figure S4D). Imatinib alone
was sufﬁcient to counteract the survival signals that keep
HIV-1–infected macrophages alive, and long-term exposure
to Imatinib resulted in apoptosis of wild-type–infected
macrophages even in the absence of TRAIL (Figure 6). This
ﬁnding was reﬂected by a decrease in Mcl-1 expression and a
further increase in pro-apoptotic protein expression (un-
published data). Overall, these data suggest that Imatinib may
be an effective strategy to induce the TRAIL-dependent
apoptotic death of HIV-1–infected macrophages in vivo. Our
results also raise the intriguing possibility that Imatinib may
be able to promote the death of infected macrophages
without the need for TRAIL.
Discussion
In this study, we present evidence for a novel envelope-
dependent mechanism that allows HIV-1–infected macro-
phages to persist in the face of apoptotic clearance processes.
Furthermore, we describe a chemotherapeutic agent, Imati-
nib, which has the potential to disable this viral defense.
Figure 7 summarizes the mechanisms employed by the HIV-1
envelope glycoprotein to subvert the host apoptotic response
to TRAIL in infected macrophages, as well as those processes
countered by Imatinib to restore TRAIL sensitivity and
induce apoptosis. Apoptosis by TRAIL can be propagated by
signals via intrinsic or extrinsic pathways [24]. However,
TRAIL-mediated apoptosis in macrophages was dependent
upon the extrinsic or mitochondrial pathway of apoptosis.
Despite the HIV-1 envelope-dependent upregulation of IAP
family proteins (which can block the extrinsic pathway) early
in infection, signals from the TRAIL receptor that promoted
apoptosis through the mitochondrial pathway were dominant
in HIV-infected macrophages. This ﬁnding agrees with Zheng
et al. [28], who report that human primary monocytes resist
TRAIL-mediated apoptosis through Bcl-2–dependent (mito-
chondrial) mechanisms. The exact molecular basis for the
regulation of pro-survival and anti-apoptotic factors by HIV-
Figure 3. M-CSF Modulates TRAIL-R1 Expression
(A) HIV-1 wild-type–, Denv-, or mock-infected macrophages were analyzed by flow cytometry 16 h after treatment with recombinant M-CSF (5,000 pg/
ml
 1) or with a neutralizing antibody to M-CSF (error bars, SD).
(B,C) HIV-1 envelope is required for the resistance of infected macrophages to TRAIL. HIV-1 wild-type– and Denv-infected macrophages were incubated
with neutralizing antibody to M-CSF for 16 h. Cultures were then treated with soluble TRAIL (100 ng/ml
 1). Cell viability (B) and virus output (C) were
determined after 24 h by MTT assay and RT production, respectively.
doi:10.1371/journal.ppat.0030134.g003
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HIV-1 Envelope and Macrophage ApoptosisFigure 4. M-CSF Upregulates Host Anti-Apoptotic Genes to Mediate Resistance of Infected Macrophages to TRAIL
(A) mRNA levels for the anti-apoptotic genes Bfl-1 and Mcl-1 were measured by ribonuclease protection assay in HIV-1 wild type– and Denv-infected
macrophage cultures incubated in the presence or absence of M-CSF.
(B) RNAi effectively mediated substantial reduction in Bfl-1 and Mcl-1 protein levels in human macrophages. Protein levels were determined by Western
blotting and normalized to signals from tubulin.
(C) RNAi-mediated Bf1–1 and Mcl-1 knockdown of mRNAs. mRNA levels, determined by quantitative RT-PCR, are shown as percentage relative to a
scrambled siRNA (SCR1) (error bars, SD).
(D) Bfl-1 and Mcl-1 are required for protection from TRAIL-mediated apoptosis. Macrophages were transfected with Mcl-1, Bfl-1, or a nontargeting
control (SCR1) siRNA. Sixteen hours later, macrophages were treated with soluble TRAIL, or an antibody to M-CSF, and apoptosis was determined by
ELISA for active (cleaved) caspase 3 (error bars, SD).
doi:10.1371/journal.ppat.0030134.g004
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HIV-1 Envelope and Macrophage ApoptosisFigure 5. Imatinib Blocks M-CSF Signaling and Restores TRAIL Sensitivity of Infected Macrophages
(A) Imatinib inhibits M-CSF–dependent autophosphorylation of the M-CSF receptor. Macrophages were incubated for 16 h with 2 lM Imatinib mesylate
before stimulation with recombinant M-CSF for 5 min. The M-CSF receptor was immunoprecipitated from cell lysates, and M-CSF–dependent tyrosine
autophosphorylation was determined by Western blotting and densitometry.
(B) Imatinib upregulates TRAIL-R1 expression on wild-type–infected macrophages. HIV-1 wild-type– and Denv-infected macrophages were incubated
with Imatinib for 16 h and TRAIL-R1 levels were determined by flow cytometry.
(C) Macrophages from three donors were treated as in (B), and statistical analysis was performed on the mean expression of TRAIL-R1 in response to
Imatinib (ANOVA; error bars, SEM).
(D) Imatinib restores sensitivity to TRAIL. Macrophages were incubated with Imatinib for 16 h, challenged with soluble TRAIL, or both. Apoptotic HIV-1–
infected and uninfected cells in the same cultures were determined 6 h later by Annexin V and propidium iodide staining and flow cytometry.
Apoptotic cells were Annexin V
þ, propidium iodide
  (lower right quadrant). Imatinib renders HIV-1 wild-type–infected macrophages susceptible to
TRAIL-mediated apoptosis.
(E) Macrophages were treated as in (D), except apoptosis was determined 16 h after TRAIL exposure by ELISA for apoptotic histone-associated cellular
DNA fragmentation in macrophage lysates (cell death ELISA; error bar, SD).
doi:10.1371/journal.ppat.0030134.g005
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e134 1287
HIV-1 Envelope and Macrophage Apoptosis1 envelope is under investigation through mutagenesis
studies and analysis of signal transduction pathways inﬂu-
enced by envelope expression.
The dissemination of HIV-1 from infected macrophages to
neighboring T lymphocytes requires intimate cell–cell con-
tact, which can leave infected macrophages susceptible to
apoptosis by death ligands on lymphocytes. TRAIL cytotox-
icity is mediated effectively by CD4
þ T lymphocytes and by
CD8
þ T cells and NK cells [29,30]. In vivo, macrophages can
undergo apoptosis after activating CD4
þ T cells. The
induction of macrophage apoptosis by TRAIL on CD4
þ T
cells has been proposed to form part of macrophage
homeostasis during antigen presentation [4]. The regulation
of activated macrophages by TRAIL also serves to limit
immune responses and to target macrophages infected with
intracellular organisms for elimination [31]. For these
reasons, the avoidance of apoptosis by TRAIL is likely an
important process for the survival of HIV-1–infected macro-
phages in vivo. Macrophages infected by HIV-1 did not
express receptors for other death ligands; neutralizing
TRAIL—but not the Fas ligand or TWEAK—on T lympho-
cytes prevented the apoptosis of infected macrophages when
the protective functions of the viral envelope were disabled.
These ﬁndings suggest TRAIL is a major restriction for the
persistence of HIV-1 in macrophages during interactions
with immune cells.
Mechanisms that restrict TRAIL-mediated apoptosis have
been described for several unrelated viruses. Gamma-herpes-
viruses, including Kaposi sarcoma-associated human herpes-
virus-8, encode FLICE-inhibitory proteins (FLIPs) that
interact with the adaptor protein FADD to inhibit the
generation of active caspase 8, which is necessary to trigger
apoptosis by TRAIL [32]. Human adenovirus type-5 encodes
three proteins (RID) that induce the internalization from the
cell surface and lysosomal degradation of TRAIL receptors
[10]. Human T cell leukemia virus type 1–infected T cell lines
are also resistant to TRAIL-mediated apoptosis, presumably
because of activation of TRAIL expression by the viral
transactivator Tax [33]. Apoptosis of B cells by TRAIL is
inhibited by the Epstein-Barr virus–encoded BHRF1 protein,
which functions in the apoptotic pathway similarly to the host
protein Bﬂ-1 that is induced by M-CSF in HIV-1–infected
macrophages [34,35]. TRAIL-R1 is speciﬁcally downregulated
in cells infected by human herpesvirus 7 and is associated
with their resistance to TRAIL-mediated cytotoxicity [36].
Figure 7. Experimental Model: Following HIV-1 Infection, De Novo Synthesized Viral Envelope Induces the Release of M-CSF
M-CSF opposes TRAIL by suppressing TRAIL-R1 expression and upregulating the anti-apoptotic factors Bfl-1 and Mcl-1. The anti-cancer drug Imatinib
disables the protective effect of envelope by inhibiting M-CSF activity. Upon inhibition of M-CSF activity, TRAIL-R1 expression is increased and the
action of Bfl-1 and Mcl-1 is blocked by pro-apoptotic bcl-2 family proteins. Further exposure of infected macrophages to Imatinib for several days
induces apoptosis in the absence of TRAIL and is associated with increased pro-apoptotic protein expression.
doi:10.1371/journal.ppat.0030134.g007
Figure 6. Prolonged Exposure to Imatinib Alone Is Sufficient to Induce
Apoptosis in HIV-1–Infected Macrophages
Five days after infection with HIV-1LAI wild-type or Denv viruses,
macrophages were incubated with Imatinib for 24 or 120 h, and levels
of apoptosis were determined by ELISA for histone-associated cellular
DNA fragmentation in macrophage lysates (cell death ELISA; error bars,
SD).
doi:10.1371/journal.ppat.0030134.g006
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HIV-1 Envelope and Macrophage ApoptosisOur demonstration that HIV-1 envelope glycoprotein also
counteracts TRAIL-mediated apoptosis underscores the
general importance of evading the immune pressure exerted
by TRAIL in order for viruses to persist in the infected cell.
Materials and Methods
Antibodies and reagents. Neutralizing antibody to human M-CSF
and isotype control antibody were used at 10 lg/ml
 1 and obtained
from R & D Systems. ELISA kits for human M-CSF, recombinant
soluble TRAIL-R1, and control receptor proteins were also supplied
by R & D Systems. HSA (murine CD24), Fas and TWEAK-R antibodies
for ﬂow cytometry, and antibodies to CD3 and CD28 were purchased
from BD Pharmingen. TRAIL-R1/DR4 antibody and soluble human
recombinant TRAIL were obtained from Axxora LLC. Monoclonal
and polyclonal antibodies to the M-CSF receptor and antibodies to
phosphotyrosine and tubulin were purchased from Santa Cruz
Biotech. Antibodies to Bﬂ-1 and Mcl-1 were supplied by Cell
Signaling Technologies. Imatinib mesylate was obtained from
Sequoia Research Products.
Cells and viruses. The R5 tropic virus HIV-1ADA was prepared as
detailed previously [18,37]. For the preparation of HIV-1 X4-tropic
LAI and HSA viruses pseudotyped with the VSV envelope, 293 T cells
were co-transfected with 25 lg of HIV-1 DNA and 25 lg of a VSV-G
expression vector by Calcium Phosphate precipitation. Viruses
containing supernatants were harvested 60 h post-transfection and
standardized by RT assay as described previously [18,37]. HIV-1HSA
[38] contains the mouse gene CD24, a heat stable surface antigen, in
place of Vpr. As a result, HIV-1HSA–infected cells can be identiﬁed by
ﬂow cytometry, and pseudotyping with VSV-G envelope effectively
bypasses the requirement for Vpr in macrophage infection. Envelope-
minus HIV-1LAI and HIV-1HSA variants were constructed by Nde I
restriction site ﬁll-in. HIV-1LAIDCD4b contains a two amino acid
deletion in a critical CD4-receptor binding domain of HIV-1 envelope
that disrupts CD4 binding [21]. Lymphocytes and monocytes were
obtained by leukapheresis from normal donors seronegative for HIV-
1 and hepatitis B. Populations of CD8
þ T lymphocytes were obtained
by additional puriﬁcation with antibody-coated magnetic beads
according to manufacturer’s instructions (Dynal-Invitrogen). The
lymphocytes were activated with antibodies to CD3 and CD28 (5 lg/
ml
 1 each) for 48 h and washed in medium prior to co-culture
experiments with macrophages. Monocytes were further separated by
countercurrent centrifugal elutriation as detailed elsewhere [39].
Elutriated monocytes were differentiated from macrophages by
culture for 4 d in medium containing M-CSF (R & D Systems) and
for a further 3 d in medium without M-CSF. Macrophages were then
used for virus infections within 1–5 d.
Apoptosis, cell death, and viability assays. ELISAs for determining
apoptosis by the cleavage of caspase 3 (to active form) were obtained
from Cell Signaling Technologies. Brieﬂy, 1.4 3 10
6 macrophages
infected with wild-type and envelope-minus viruses were lysed
according to the supplier’s protocol 1 h after the addition of soluble
recombinant TRAIL (100 ng/ml
 1). Protein content was determined by
Bradford Assay (Bio-Rad), and 220 lg of protein in 200 ll from each
culture was assayed in ELISA. Reagents were purchased from
BioVision and used according to the supplier’s protocol for the
measurement of apoptosis by Annexin V and propidium iodide
staining in ﬂow cytometry. Apoptotic DNA fragmentation was
measured by ELISA for histone-associated DNA fragments present
in macrophage lysates prepared according to the manufacturer’s
instructions (Roche) 16 h after exposure to apoptotic stimuli. For the
determination of macrophage longevity, cell death was quantitated by
ELISA for the release of histone-associated fragmented DNA into
macrophage culture supernatants (Roche). Brieﬂy, after the addition
of soluble TRAIL to 0.7310
6 cells, 10 ll of supernatant was harvested
over time for ELISA. Supernatant from macrophages treated for 72 h
with 100 lM Apoptosis Activator I (EMD Biosciences), which resulted
in comprehensive visual cell death, was used as a positive control and
as a value for remaining viable cells calculated by subtraction. In other
experiments, an MTT assay (Sigma) was used to measure cell viability.
T cell–mediated inhibition of viral replication. Infected macro-
phages were monitored by RT assay until viral replication
approached peak. The medium was changed, and anti-CD3/CD28
stimulated autologous CD8
þ T cells (2.5 3 10
6) after incubation with
soluble TRAIL-R1 or control receptor for 1 h were co-cultured with
infected macrophages for 4 h. The CD8 cells were then gently
removed and virus production from macrophages determined by RT
assay 24 h later.
RNA interference and quantitation. Macrophages, 1.4 3 10
6, were
infected with wild-type HIV-1 LAI and a Denv variant and monitored
by RT assay until viral replication approached peak levels. Macro-
phages were transfected with Lipofectamine 2000 containing 100 nM
duplexed small interfering RNA (siRNA) to Bﬂ-1, Mcl-1, or scrambled
siRNA (Dharmacon) for 4 h, then re-fed conditioned medium from
uninfected macrophages. The transfection was repeated the next day.
Cells were harvested for ELISA or RNA analysis 16 h after the second
transfection. RNA interference (RNAi)–mediated mRNA decay was
assessed on total RNA from 200,000 cells prepared by Trizol
(Invitrogen) in SyBr Green real time RT-PCR (Quantitect SyBr Green
Kit; Qiagen) using gene-speciﬁc primers from SuperArray. The levels
of cellular mRNAs were similarly determined by SyBr Green real-time
PCR or by ribonuclease protection assay (BD Pharmingen), as
described previously [37].
Statistical analyses. The statistical signiﬁcance of data, where
indicated, was determined by ANOVA or t-test using Prism 5
(GraphPad Software). Mean values 6 SEM are shown graphically;
annotations indicate the conﬁdence level (p-value) and number of
replicates (n).
Supporting Information
Figure S1. M-CSF Production by Infected Macrophages Is Not
Dependent on Envelope-CD4 Interaction
Virus production (A) and M-CSF release (B) were examined following
infection with pseudotyped HIV-1 variants containing intact or
deleted envelope genes or an HIV-1 mutant (HIV-1LAIDCD4b) lacking
a functional CD4 receptor binding motif in envelope. Cumulative M-
CSF release (C) during the course of viral replication was determined
by normalizing the amount of M-CSF to RT output (error bars, SD).
(D) The incubation of cell-free HIV-1 virions with macrophages does
not promote M-CSF release. R5-tropic HIV-1ADAWT and HIV-
1ADADenv viruses were VSV-G pseudotyped and were puriﬁed on
continuous 15%–60% sucrose gradients. Individual gradient frac-
tions were dialyzed, analyzed for RT activity, and added to macro-
phage cultures for 1 h. M-CSF production was determined after 16 h
by ELISA. Gradient fractions of mock-infected macrophage super-
natants were used as controls.
Found at doi:10.1371/journal.ppat.0030134.sg001 (356 KB PDF).
Figure S2. HIV-1 Envelope Regulates Host Genes Involved in
Apoptotic Pathways
Messenger RNA levels were compared in cDNA gene arrays between
macrophages infected with pseudotyped X4 wild-type HIV-1 and an
envelope-minus variant 5 d post-infection. Gene expression was
considered signiﬁcantly different when the variation was  1.7 units
[40].
Found at doi:10.1371/journal.ppat.0030134.sg002 (259 KB PDF).
Figure S3. Macrophages Exhibit Moderate Resistance to TRAIL at
Intervals Post-Infection when M-CSF Levels in Culture Supernatants
Are Low
(A) M-CSF levels in HIV-1 wild-type– and Denv-infected macrophages
at different intervals post-infection. M-CSF induction is not apparent
during the ﬁrst 4 d post-infection.
(B) Sensitivity of infected macrophages to TRAIL at 2 d (no M-CSF in
culture supernatants) and 8 d (elevated M-CSF in culture super-
natants) post-infection (error bars, SD).
(C) Analysis of apoptosis-related gene expression at different
intervals post-infection. Three anti-apoptotic genes (cIAP-1, cIAP-2,
XIAP) were upregulated in an HIV-1 envelope-dependent manner
even at 2 d post-infection when M-CSF levels in culture supernatants
were undetectable. mRNA levels were determined by quantitative RT-
PCR.
Found at doi:10.1371/journal.ppat.0030134.sg003 (352 KB PDF).
Figure S4. Macrophages Infected with R5-tropic HIV-1ADA Regulate
TRAIL-R1 Expression Via M-CSF Release and Succumb to TRAIL-
Mediated Apoptosis Only in the Presence of Imatinib
(A) HIV-1ADA induced infected macrophages to release M-CSF during
viral replication.
(B) TRAIL-R1 expression on HIV-1ADA wild-type– or mock-infected
macrophages was analyzed by ﬂow cytometry 16 h after treatment
with recombinant M-CSF (5,000 pg/ml
 1) or with a neutralizing
antibody to M-CSF (error bars, SD).
(C) Imatinib renders HIV-1ADA wild-type–infected macrophages
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e134 1289
HIV-1 Envelope and Macrophage Apoptosissensitive to TRAIL-mediated apoptosis. HIV-1ADA wild-type– and
mock-infected macrophages were incubated with Imatinib for 16 h
and stimulated with TRAIL. Apoptosis was determined by ELISA for
active (cleaved) caspase 3 (error bars, SD).
Found at doi:10.1371/journal.ppat.0030134.sg004 (308 KB PDF).
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